Clinical trials: Central Nervous System
Multiple Sclerosis
A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
The primary purpose of this study is to demonstrate pharmacokinetic bioequivalence of ofatumumab injected by Pre-filled Syringe (PFS) versus Auto-Injector (AI) devices and thereby establish a bridge between the ongoing Phase 3…
- Trial name
- NCT03560739
- Testing
- ofatumumab with PRF, ofatumumab with AI
- Where
- 41 sites in United States, Austria and 7 more
- Volunteers
- 284 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy
SP848 is an open-label study to evaluate long-term safety, tolerability, and efficacy in children with epilepsy treated with Lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy.
- Trial name
- NCT00938912
- Testing
- Lacosamide
- Where
- 69 sites in United States, Belgium and 9 more
- Volunteers
- 366 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Alzheimer's Disease
A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
The purpose of this study is determine whether a single IV dose of PF-04360365 is safe and well tolerated in Adults with Mild to Moderate Alzheimer's disease.
- Trial name
- NCT00455000
- Testing
- PF-04360365
- Where
- 12 sites in Australia, Canada and 2 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
Parkinson's Disease
Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)
This study is being done to assess the pharmacokinetics of SCH 900800 in participants with moderate to severe Parkinson's Disease (PD) being treated with L-DOPA.
- Trial name
- NCT01500707
- Testing
- SCH 900800
- Sponsor
- Merck Sharp & Dohme LLC
Friedreich Ataxia, Friedreich's Ataxia
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
To evaluate the efficacy and safety of subcutaneous nomlabofusp in adult and pediatric subjects with Friedreich's ataxia
- Trial name
- FORWARD-FA (NCT07778836)
- Testing
- Nomlabofusp
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- Larimar Therapeutics, Inc.
Chronic Cluster Headache
Cephalic Vascular Recording Upon SPG Stimulation
Hypothesis: Stimulation of the SPG at high frequencies (50-200Hz) is believed to cause a physiological parasympathetic block which decreases VMCA oxyHb concentration and cephalic vessel diameter.
- Trial name
- NCT01359631
- Volunteers
- 7 people
- Sponsor
- Autonomic Technologies, Inc.
CNS Lymphoma
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
This will be an open-label, single-arm, national phase 1/2 therapeutic study to evaluate the safety, tolerability, and preliminary efficacy of [90Y]Y-PentixaTher ([90Y]Y-PTT) for the treatment of recurrent or refractory primary…
- Trial name
- NCT06132737
- Testing
- [90Y]Y-PentixaTher
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Pentixapharm AG
Parkinson Disease, Dyskinesia, Medication-Induced
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia
The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia.
- Trial name
- NCT05297201
- Testing
- CPL500036 - low dose, CPL500036 - high dose
- Where
- 16 sites in Poland, Ukraine
- Volunteers
- 105 people
- Sponsor
- Celon Pharma SA
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
The purpose of the study is to evaluate the efficacy of IFX-1 treatment as replacement for glucocorticoid (GC) therapy in subjects with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Trial name
- IXchange (NCT03895801)
- Testing
- IFX-1, Glucocorticoid (GC)
- Where
- 76 sites in Belgium, Czechia and 9 more
- Volunteers
- 57 people
- Sponsor
- InflaRx GmbH
Intracerebral Hemorrhage (ICH)
GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage
The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage.
- Trial name
- NCT01298830
- Testing
- GLP-1 CellBeads
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- CellMed AG, a subsidiary of BTG plc.
Episodic Migraine
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have failed other preventive migraine treatments.
- Trial name
- NCT03096834
- Testing
- AMG334 (70 mg) Pre-Filled Syringe (PFS)
- Where
- 59 sites in Australia, Austria and 14 more
- Volunteers
- 246 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme, Brain Tumor
Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients
This study is to evaluate the safety and find the tolerated ultrasound dose of transient opening of the blood-brain barrier (BBB) by using the NaviFUS System in recurrent GBM patients.
- Conditions
- Glioblastoma Multiforme, Brain Tumor, Glioblastoma, Glioma
- Trial name
- NCT03626896
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
- Trial name
- NCT07365462
- Testing
- NBI-1065890
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Fabry Disease
Treatment Protocol of Replagal for Patients With Fabry Disease
The study will evaluate the safety and efficacy of Replagal® (agalsidase alfa) at a dose of 0.2 mg/kg infused intravenously (IV) over 40 minutes, every other week.
- Trial name
- NCT01031173
- Testing
- agalsidase alfa
- Where
- 25 sites in United States
- Sponsor
- Shire
Alzheimer Disease
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
The goal of the proposed study, is to adapt a positive emotion intervention for Alzheimer's Disease (AD) caregivers into a self-guided online format that incorporates social connection components and adaptive system feedback…
- Trial name
- SAGE-LEAF (NCT05562583)
- Testing
- SAGE LEAF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- BrightOutcome
Migraine
Machine Learning Assessment of Next-Day Migraine Likelihood
Development of a machine learning (ML) algorithm for assessment of next-day migraine likelihood, drawing on self-reported migraine-related information, and geographic location, collected via the Nerivio app- a mobile application…
- Trial name
- NCT07227194
- Where
- United States
- Volunteers
- 53,065 people
- Sponsor
- Theranica
Epilepsy
A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning (USF)
Increased computational power has made it possible to implement complex image recognition tasks and machine learning to be implemented in every day usage.
- Trial name
- NCT06705439
- Testing
- Nelli
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Neuro Event Labs Inc.
Alzheimer's Disease
Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease
Efficacy and safety study of ABT-288 in adults with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT01018875
- Testing
- ABT-288, donepezil
- Where
- 21 sites in Russia, Ukraine
- Volunteers
- 242 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Brain Diseases, Vertebral Artery Thrombosis
A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX
Aprospective, multicentre, single-arm clinical trial in which approximately 36 subjects would be enrolled using the Bridge 4.5 mm and 5.0 mm stent in accordance with the inclusion and exclusion criteria in this protocol.
- Conditions
- Brain Diseases, Vertebral Artery Thrombosis, Vertebral Artery Stenosis
- Trial name
- NCT06186024
- Testing
- Bridge
- Where
- China
- Volunteers
- 36 people
- Sponsor
- MicroPort NeuroTech Co., Ltd.
Bardet-Biedl Syndrome, POMC Deficiency
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
- Trial name
- NCT05194124
- Testing
- Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg
- Where
- 7 sites in United States, Canada and 4 more
- Volunteers
- 19 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.